Amgen’s Pharma-Style Reorganization Includes Staff Cuts, Pipeline Prioritization
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As Amgen enters into a major restructuring effort that will include extensive cost-cutting and significant headcount reductions, it will also make serious adjustments to its R&D program – including scaling back from its industry-leading approach of investing a high percentage of sales on R&D.